Skip to main content
. Author manuscript; available in PMC: 2014 Dec 2.
Published in final edited form as: Mol Pharm. 2013 Nov 12;10(12):4676–4686. doi: 10.1021/mp400487f

Figure 1.

Figure 1

Schematic representation for the preparation of bevacizumab encapsulated porous PLGA microparticles prepared by supercritical pressure quench technology. (A) Plain PLGA microparticles were made porous by supercritical pressure quench technology and bevacizumab was loaded (PMP1). (B) Bevacizumab was coated on plain PLGA microparticles and exposed to supercritical CO2 (PMP2). The release was performed in PBS pH 7.4 and bevacizumab content was estimated using a micro-BCA kit. Results are expressed as mean ± SD for n=3.